详情页

资源类型：

文章类型：

作者：

Xu, Wei[1] * ; Song, Yongping[2] ; Wang, Tingyu[3] ; Yang, Shenmiao[4] ; Liu, Lihong[5]

; Hu, Yu[6] ; Zhang, Wei[7] ; Zhou, Jianfeng[8] ; Gao, Sujun[9] ; Ding, Kaiyang[10] ; Zhang, Huilai[11] ; Zhu, Zunmin[12] ; Wang, Shunqing[13] ; Xu, Bing[14] ; Hu, Jianda[15] ; Liu, Ting[16] ; Ji, Chunyan[17] ; Xia, Zhongjun[18] ; Li, Yan[19] ; Wang, Xin[20] ; Bin Zhang[21] ; Zhao, Renbin[21] ; Li, Jianyong[1] ;

机构： [1]Nanjing Med Univ, Affiliated Hosp 1, Jiangsu Prov Hosp,Dept Hematol,Pukou CLL Ctr, Collaborat Innovat Ctr Canc Personalized Med, Nanjing, Peoples R China [2]Zhengzhou Univ, Affiliated Canc Hosp, Dept Hematol, Zhengzhou, Peoples R China [3]Chinese Acad Med Sci & Peking Union Med Coll, Blood Dis Hosp & Inst Hematol, Natl Clin Res Ctr Blood Dis, State Key Lab Expt Hematol, Tianjin, Peoples R China [4]Peking Univ Peoples Hosp, Peking Univ Inst Hematol, Hematol, Beijing, Peoples R China [5]Hebei Med Univ, Hosp 4, Dept Hematol, Shijiazhuang, Hebei, Peoples R China [6]Huazhong Univ Sci & Technol, Union Hosp, Inst Hematol, Tongji Med Coll, Wuhan, Peoples R China [7]Chinese Acad Med Sci & Peking Union Med Coll, Dept Hematol, Peking Union Med Coll Hosp, Beijing, Peoples R China [8]Huazhong Univ Sci & Technol, Tongji Hosp, Dept Hematol, Tongji Med Coll, Wuhan, Peoples R China [9]Jilin Univ, Hosp 1, Dept Hematol, Changchun, Peoples R China [10]First Affiliated Hosp Univ Sci & Technol China, Anhui Prov Hosp, Dept Hematol, Hefei, Peoples R China [11]Tianjin Med Univ Canc Inst & Hosp, Dept Lymphoma,Key Lab Canc Prevention & Therapy, Natl Clin Res Ctr Canc,Tianjins Clin, Tianjins Clin Res Ctr Canc, Tianjin, Peoples R China [12]Henan Prov Peoples Hosp, Inst Hematol, Zhengzhou, Peoples R China [13]Guangzhou First Peoples Hosp, Dept Hematol, Guangzhou, Peoples R China [14]Xiamen Univ, Affiliated Hosp 1, Dept Hematol, Xiamen, Peoples R China [15]Fujian Med Univ Union Hosp, Fujian Inst Hematol, Dept Hematol, Fujian Prov Key Lab Hematol, Fuzhou, Peoples R China [16]Sichuan Univ, West China Hosp, Dept Hematol, Chengdu, Peoples R China [17]Shandong Univ, Qilu Hosp, Dept Hematol, Cheeloo Coll Med, Jinan, Peoples R China [18]Sun Yat sen Univ Canc Ctr, Dept Hematol Oncol, Collaborat Innovat Ctr Canc Med, State Key Lab Oncol South China, Guangzhou, Peoples R China [19]China Med Univ, Hosp 1, Dept Hematol, Shenyang, Peoples R China [20]Shandong Univ, Shandong Prov Hosp, Dept Hematol, Jinan, Shandong, Peoples R China [21]Beijing InnoCare Pharma Tech Co Ltd, Beijing, Peoples R China

出处：

DOI：

ISSN：

语种：

被引次数：

WOS：

中科院分区：

出版当年[2021]版：

大类 | 1 区

医学

小类 | 1 区血液学

最新[2025]版：

大类 | 1 区

医学

小类 | 1 区血液学

JCR分区：

出版当年[2021]版：

Q1 HEMATOLOGY

最新[2024]版：

Q1 HEMATOLOGY

第一作者：

第一作者机构： [1]Nanjing Med Univ, Affiliated Hosp 1, Jiangsu Prov Hosp,Dept Hematol,Pukou CLL Ctr, Collaborat Innovat Ctr Canc Personalized Med, Nanjing, Peoples R China

推荐引用方式(GB/T 7714)：

APA：

MLA：

Orelabrutinib Monotherapy in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma: Updated Long Term Results of Phase II Study

文献详情